Differential effects of amphetamine and neuroleptics on negative Vs. positive symptoms in schizophrenia
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Positive symptoms of schizophrenia were diminished by neuroleptics and increased by amphetamine and accounted for most of the change seen in the total Brief Psychiatric Rating Scale (BPRS). Negative symptoms in the same subjects were not affected by neuroleptics but increased after amphetamines to a degree that just attained statistical significance. This increase was due to one item (emotional withdrawal) of the negative symptom factor which responded to neuroleptics and amphetamines as did positive symptoms. These findings are discussed with respect to new ideas about the role of dopamine in schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Administration of stimulants to unmedicated schizophrenic patients can enhance positive symptoms (Angrist et al 1980, van Kammen et al 1982), which is likely due to subcortical D2 receptor activation.”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Angrist et al 1980, van Kammen et al 1982
Citations
Cites
Research Diagnostic Criteria: Rationale and Reliability
Spitzer, R. L. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770300115013 · Cited by 6,951
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,856
CEREBRAL VENTRICULAR SIZE AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA
Johnstone, E., Frith, C. D., Crow, T. J., Husband, J., & Kreel, L. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90890-4 · Cited by 1,253
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Kono, R., Miyamura, K., OGINO, T., Wadia, N. H., Wadia, P. N., Sm, K., & Vp, M. (1981) · PubMed · Cited by 578
MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA
Johnstone, E., Frith, C. D., Crow, T. J., Carney, M. W. P., & Price, J. S. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90193-9 · Cited by 458
Hormones, Behavior, and Psychopathology
SACHAR, E. J. (1977) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197709000-00013 · Cited by 330
Weinberger, D. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140013001 · Cited by 323
The dementia of dementia praecox
Johnstone, E. C., Crow, T. J., Frith, C. D., Stevens, M., Kreel, L., & Husband, J. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb06899.x · Cited by 270
Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects
Angrist, B., Rotrosen, J., & Gershon, S. (1980) · Psychopharmacology · doi:10.1007/bf00427592 · Cited by 140
Self-citation
Research works printed but not linked: 1
- Guy W (1976) E.C.D.E.U. assessment manual for psychopathology. Washington D.C.: U.S. Department of Health, Education and Welfare, pp 160, 162, 167
Cited by
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Negative v Positive Schizophrenia: Definition and Validation
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,012
Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
The neuropsychology of schizophrenia
Gray, J. A., Feldon, J., Rawlins, J. N. P., Hemsley, D. R., & Smith, A. D. (1991) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00065055 · Cited by 1,350
The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291514 · Cited by 1,016
Reliability and validity of the positive and negative syndrome scale for schizophrenics
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90038-8 · Cited by 1,007
The Two-syndrome Concept: Origins and Current Status
Crow, T. J. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.471 · Cited by 839
Symptoms of Schizophrenia: Methods, Meanings, and Mechanisms
Andreasen, N. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950170015003 · Cited by 734
Frith, C. D. (1987) · Psychological Medicine · doi:10.1017/s0033291700025873 · Cited by 655
Prevalence of Substance Abuse in Schizophrenia: Demographic and Clinical Correlates
Mueser, K. T., Yarnold, P. R., Levinson, D. F., Singh, H., Bellack, A. S., Kee, K., Morisson, R. L., & Yadalam, K. G. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.1.31 · Cited by 587
Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia
Peralta, V., & Cuesta, M. J. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90093-0 · Cited by 583
Positive and Negative Schizophrenic Symptoms and the Role of Dopamine
Crow, T. J. (1980) · British Journal of Psychiatry · doi:10.1192/s0007125000071919 · Cited by 562
Provocative tests with psychostimulant drugs in schizophrenia
Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 532
Gating of information flow within the limbic system and the pathophysiology of schizophrenia
Grace, A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00049-1 · Cited by 519
Symptomatic and Neuropsychological Components of Defect States
Bilder, R. M., Mukherjee, S., Rieder, R. O., & Pandurangi, A. K. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.409 · Cited by 504
Treatment of Negative Symptoms
Carpenter, W. T., Heinrichs, D. W., & Alphs, L. D. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.440 · Cited by 499
Schizophrenia: The Characteristic Symptoms
Andreasen, N. C., & Flaum, M. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.1.27 · Cited by 426
Verbal hallucinations and language production processes in schizophrenia
Hoffman, R. E. (1986) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00046781 · Cited by 364
Tandon, R. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810080075010 · Cited by 351
Negative Symptoms in Schizophrenia: Their Longitudinal Course and Prognostic Importance
Pogue-Geile, M. F., & Harrow, M. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.427 · Cited by 345
Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics
Swerdlow, N. R., Braff, D. L., Geyer, M. A., & Koob, G. F. (1986) · Biological Psychiatry · doi:10.1016/0006-3223(86)90005-3 · Cited by 340
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 336
Positive vs. Negative Schizophrenia: A Critical Evaluation
Andreasen, N. C. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.380 · Cited by 332
Jentsch, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00034-1 · Cited by 320
Attentional Vulnerability Indicators, Thought Disorder, and Negative Symptoms
Nuechterlein, K. H., Edell, W. S., Norris, M., & Dawson, M. E. (1986) · Schizophrenia Bulletin · doi:10.1093/schbul/12.3.408 · Cited by 300
An integrative perspective on the role of dopamine in schizophrenia
Maia, T. V., & Frank, M. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.021 · Cited by 293
“Interestingly, amphetamine has in fact sometimes been reported to aggravate negative symptoms (116).”
Negative and Positive Symptoms in Schizophrenia and Depression: A Followup
Pogue-Geile, M. F., & Harrow, M. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.371 · Cited by 261
Pickar, D., Labarca, R., Linnoila, M., Roy, A., Hommer, D., Everett, D., & Paul, S. M. (1984) · Science · doi:10.1126/science.6474162 · Cited by 246
Farkas, T. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790140083010 · Cited by 233
Khat use as risk factor for psychotic disorders: A cross-sectional and case-control study in Somalia
Odenwald, M., Neuner, F., Schauer, M., Elbert, T., Catani, C., Lingenfelder, B., Hinkel, H., Häfner, H., & Rockstroh, B. (2005) · BMC Medicine · doi:10.1186/1741-7015-3-5 · Cited by 232
Treatment of Negative Symptoms in Schizophrenia with Amisulpride
Boyer, P., Lecrubier, Y., Puech, A. J., Dewailly, J., & Aubin, F. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.1.68 · Cited by 229
Dixon, L., Haas, G., Weiden, P., Sweeney, J., & Frances, A. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.1.69 · Cited by 223
The role of 5-HT2A receptors in antipsychotic activity
Schmidt, C. J., Sorensen, S. M., Kenne, J. H., Carr, A. A., & Palfreyman, M. G. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00210-w · Cited by 215
Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.2.151 · Cited by 213
Neuropathological Studies of Schizophrenia: A Selective Review
Weinberger, D. R., Wagner, R. L., & Wyatt, R. J. (1983) · Schizophrenia Bulletin · doi:10.1093/schbul/9.2.193 · Cited by 212
The role of serotonin in the pathophysiology and treatment of schizophrenia
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.1.1 · Cited by 211
Significance of Positive and Negative Syndromes in Chronic Schizophrenia
Kay, S. R., Opler, L. A., & Fiszbein, A. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.4.439 · Cited by 195
O'Donnell, P., & Grace, A. A. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033325 · Cited by 193
Neuroleptic responsivity of negative and positive symptoms in schizophrenia
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.12.1549 · Cited by 190
Lubow, R. E. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi005 · Cited by 189
Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia
Grace, A. A. (1993) · Journal of Neural Transmission · doi:10.1007/bf01245228 · Cited by 185
The potential adverse effects of habitual use of Catha edulis(khat)
Al-Habori, M. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.1145 · Cited by 178
Positive and Negative Schizophrenic Symptoms, Attention, and Information Processing
Cornblatt, B. A., Lenzenweger, M. F., Dworkin, R. H., & Erlenmeyer-Kimling, L. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.397 · Cited by 178
Prefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
Positive and Negative Symptoms and Jackson: A Conceptual History
Berrios, G. E. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790240097011 · Cited by 174
Stimulant Psychosis: Symptom Profile and Acute Clinical Course
Harris, D. S., & Batki, S. L. (2000) · American Journal on Addictions · doi:10.1080/10550490050172209 · Cited by 174
The Diagnosis of Schizophrenia
Andreasen, N. C. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.1.9 · Cited by 135
Proposal for a noradrenaline hypothesis of schizophrenia
Yamamoto, K.-I., & Hornykiewicz, O. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.033 · Cited by 166
Duinkerke, S. J., Botter, P. A., Jansen, A. A. I., van Dongen, P. A. M., Haaften, A. J. V., Boom, A. J., Laarhoven, J. H. M. V., & Busard, H. L. S. M. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.4.451 · Cited by 164
O'Donnell, P., & Grace, A. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-08-03456.1993 · Cited by 151
Positive-negative symptom assessment in schizophrenia: Psychometric issues and scale comparison
Kay, S. R. (1990) · Psychiatric Quarterly · doi:10.1007/bf01064966 · Cited by 155
Critical issues in assessing the behavioral effects of amphetamine
Rebec, G. V., & Bashore, T. R. (1984) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(84)90030-7 · Cited by 152
Depressive symptoms in schizophrenia: Comprehensive differential diagnosis
Bartels, S. J., & Drake, R. E. (1988) · Comprehensive Psychiatry · doi:10.1016/0010-440x(88)90062-4 · Cited by 149
Computerized tomographic scan changes in early schizophrenia – preliminary findings
Turner, S. W., Toone, B. K., & Brett-Jones, J. R. (1986) · Psychological Medicine · doi:10.1017/s003329170000266x · Cited by 137
A negative symptom rating scale
Iager, A.-C., Kirch, D. G., & Wyatt, R. J. (1985) · Psychiatry Research · doi:10.1016/0165-1781(85)90025-3 · Cited by 145
Stereotypy in monkeys and humans
Ridley, R. M., & Baker, H. F. (1982) · Psychological Medicine · doi:10.1017/s0033291700043294 · Cited by 136
Two syndromes in schizophrenia?
Crow, T. J. (1982) · Trends in Neurosciences · doi:10.1016/0166-2236(82)90202-8 · Cited by 143
Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs
Ellenbroek, B. A. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90036-d · Cited by 139
The Dopamine Hypothesis: An Overview of Studies With Schizophrenic Patients
Haracz, J. L. (1982) · Schizophrenia Bulletin · doi:10.1093/schbul/8.3.438 · Cited by 139
Evaluation of positive and negative symptoms in schizophrenia
Andreasen, N. C., & Grove, W. M. (1986) · Psychiatry and Psychobiology · doi:10.1017/s0767399x00003199 · Cited by 120
Grace, A. A. (1992) · Springer eBooks · doi:10.1007/978-3-7091-9211-5_6 · Cited by 129
Cholinergic aspects of schizophrenia
Tandon, R. (1999) · The British Journal of Psychiatry · doi:10.1192/s0007125000293586 · Cited by 129
Is the Concept of Frontal–Subcortical Dementia Relevant to Schizophrenia?
Pantelis, C., Barnes, T. R. E., & Nelson, H. E. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.160.4.442 · Cited by 128
Schmidt, C. J., & Fadayel, G. M. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)00698-7 · Cited by 126
Partial improvement in negative schizophrenic symptoms after amphetamine
ANGRIST, B. M., Peselow, E. D., Rubinstein, M. E., Corwin, J., & Rotrosen, J. (1982) · Psychopharmacology · doi:10.1007/bf00432248 · Cited by 126
Self-citationNeuropsychological performance and positive and negative symptoms in schizophrenia.
Green, M. M., & Walker, E. F. (1985) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.94.4.460 · Cited by 126
Clozapine's effect on negative symptoms in treatment-refractory schizophrenics
Miller, D. D., Perry, P. J., Cadoret, R. J., & Andreasen, N. C. (1994) · Comprehensive Psychiatry · doi:10.1016/0010-440x(94)90164-3 · Cited by 119
Symptoms and the genetics of schizophrenia: implications for diagnosis
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.12.1541 · Cited by 109
Keefe, R. S. E., Harvey, P. D., Lenzenweger, M. F., Davidson, M., Apter, S. H., Schmeidler, J., Mohs, R. C., & Davis, K. L. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90049-9 · Cited by 117
CNS stimulants as tools in the study of schizophrenia
Angrist, B., & van Kammen, D. P. (1984) · Trends in Neurosciences · doi:10.1016/s0166-2236(84)80062-4 · Cited by 117
Self-citationPositive and negative symptoms in the psychoses: Multidimensional scaling of SAPS and SANS items
Minas, I. H., Stuart, G. W., Klimidis, S., Jackson, H. J., SINGH, B., & Copolov, D. (1992) · Schizophrenia Research · doi:10.1016/0920-9964(92)90031-y · Cited by 117
Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions
Akhondzadeh, Shasavand, Jamilian, Shabestari, & Kamalipour (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00273.x · Cited by 106
Social Networks and Negative Versus Positive Symptoms of Schizophrenia
Hamilton, N. G., Ponzoha, C. A., Cutler, D. L., & Weigel, R. M. (1989) · Schizophrenia Bulletin · doi:10.1093/schbul/15.4.625 · Cited by 97
Symptom correlates of vulnerability to backward masking in schizophrenia
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.2.181 · Cited by 104
Positive and negative syndromes in schizophrenia as a function of chronicity
Kay, S. R., Fiszbein, A., Lindenmayer, J. ‐., & Opler, L. A. (1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb06276.x · Cited by 100
Multiple dopamine receptors and behavior
Joyce, J. N. (1983) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(83)90017-9 · Cited by 113
Positive and Negative Schizophrenia Symptoms and the Role of Dopamine
Crow, T. J. (1981) · British Journal of Psychiatry · doi:10.1192/bjp.139.3.251 · Cited by 100
Odenwald, M. G., Hinkel, H., Schauer, E., Schauer, M., Elbert, T. R., Neuner, F., & Rockstroh, B. S. (2009) · Social Science & Medicine · doi:10.1016/j.socscimed.2009.07.020 · Cited by 111
Chatterjee, M., Jaiswal, M., & Palit, G. (2012) · ISRN Psychiatry · doi:10.5402/2012/595141 · Cited by 108
Relationships Between Symptoms of Schizophrenia and Substance Abuse
BRUNETTE, M. F., MUESER, K. T., XIE, H., & DRAKE, R. E. (1997) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199701000-00003 · Cited by 90
Pharmacological Cognitive Enhancement in Schizophrenia
Harvey, P. D. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9103-4 · Cited by 106
Noda, Y., Kamei, H., Mamiya, T., Furukawa, H., & Nabeshima, T. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00138-x · Cited by 106
Free radical mechanisms in schizophrenia and tardive dyskinesia
Cadet, J. L., & Kahler, L. A. (1994) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(94)90001-9 · Cited by 106
The Relative Stability of Positive and Negative Features in Chronic Schizophrenia
Johnstone, E. C., Owens, D. G. C., Frith, C., & Crow, T. J. (1987) · The British Journal of Psychiatry · doi:10.1192/bjp.150.1.60 · Cited by 105
Schizophrenia: Reproductive Hormones and the Brain
Stevens, J. R. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.713 · Cited by 90
Methylphenidate treatment of negative symptoms in patients with dementia
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.2.231 · Cited by 96
Negative and positive schizophrenic syndromes after the acute phase: A prospective follow-up
Lindenmayer, J., Kay, S. R., & Friedman, C. (1986) · Comprehensive Psychiatry · doi:10.1016/0010-440x(86)90003-9 · Cited by 103
Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients
Johnstone, E. C., & Frith, C. D. (1996) · Psychological Medicine · doi:10.1017/s0033291700037685 · Cited by 92
Chronic khat use and psychotic disorders: A review of the literature and future prospects
Odenwald, M. G. (2007) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/2007.01.03 · Cited by 98
Markou, A., & Kenny, P. J. (2002) · Neurotoxicity Research · doi:10.1080/10298420290023963 · Cited by 93
Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Hogarty, G. E. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950130029004 · Cited by 83
Negative Symptomatology and Schizophrenia: A Conceptual and Empirical Review
Pogue‐Geile, M. F., & Zubin, J. (1987) · International Journal of Mental Health · doi:10.1080/00207411.1987.11449074 · Cited by 91
Lenzenweger, M. F., Dworkin, R. H., & Wethington, E. (1989) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.98.1.62 · Cited by 82
Psychiatric symptoms of noradrenergic dysfunction: A pathophysiological view
Yamamoto, K., Shinba, T., & Yoshii, M. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12126 · Cited by 88
Rating scales in research: The case of negative symptoms
Thiemann, S., Csernansky, J. G., & Berger, P. A. (1987) · Psychiatry Research · doi:10.1016/0165-1781(87)90122-3 · Cited by 83
Noorbala, A.-A., Akhondzadeh, S., Davari-Ashtiani, R., & Amini‐Nooshabadi, H. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00238.x · Cited by 86
Rund, B. R. (1993) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.102.1.74 · Cited by 81
Methylphenidate challenge as a predictor of relapse in schizophrenia
Lieberman, J. A., Kane, J. M., Gadaleta, D. J., Brenner, R., LESSER, M., & Kinon, B. J. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.5.633 · Cited by 84
Metadata
- Authors
- Angrist, B., Rotrosen, J., & Gershon, S.
- Affiliations
- United States Department of Veterans Affairs (US)
- Wayne State University (US)
- ORCID
- Rotrosen, J.
- Venue
- Psychopharmacology
- Published
- 1980-12
- Volume
- 72
- Issue
- 1
- Pages
- 17-19
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2050121560
- Cited by
- 344
- References
- 11
- Citations by year
- 2026: 1 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 2 · 2013: 4 · 2012: 8
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- amphetamine, antipsychotic drugs, schizophrenia, negative symptoms, positive symptoms, Brief Psychiatric Rating Scale, emotional withdrawal, dopamine, psychopharmacological effects
- MeSH terms
- Adult, Affect, Dextroamphetamine, Dopamine, Female, Haloperidol, Humans, Male, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.